| abstract |
Provided is a medicinal agent or a treatment method, in which a combination of an SGLT2 inhibitor and an anti-hypertension drug is used, and which is useful for the treatment of such diseases that at least hypertension or diabetes is included as a risk factor for a cardiovascular event. According to the present invention, an excellent hypotensive effect, which cannot be achieved when an anti-hypertension drug is used alone, can be achieved. Therefore, the conventional problem of using at least two types of anti-hypertension drugs for achieving a desired hypotensive effect can be solved. Furthermore, the present invention exerts a significant therapeutic effect on diabetes, a diabetes-related disease or a diabetes complication, particularly diabetic nephropathy. Furthermore, the present invention is also useful for the treatment of a disease in which the renal function is deteriorated. |